Kinnari Patel
Presidente presso ROCKET PHARMACEUTICALS, INC.
Patrimonio netto: 11 M $ in data 31/05/2024
Posizioni attive di Kinnari Patel
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Direttore operativo | 04/01/2018 | - |
| Direttore Tecnico/Scientifico/R&S | 27/03/2024 | - | |
| Presidente | - | - |
Storia della carriera di Kinnari Patel
Precedenti posizioni note di Kinnari Patel
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Direttore operativo | 01/01/2018 | 01/02/2021 |
| Consigliere Generale | 01/04/2016 | 01/12/2017 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2010 | 01/04/2014 |
Formazione di Kinnari Patel
| The Leonard N Stern School of Business | Masters Business Admin |
| University of the Sciences in Philadelphia | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Aziende private | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Kinnari Patel
- Esperienza
